



ABN 53 075 582 740

**ASX ANNOUNCEMENT**  
**28 September 2020**

---

## **Bionomics Successfully Completes Institutional Entitlement Offer**

Bionomics Limited (ASX: BNO, OTCQB:BNOEF), (**Bionomics**) is pleased to announce the successful completion of the institutional component of its 1 for 12.54 pro rata accelerated non-renounceable entitlement offer, announced on Thursday, 24 September 2020 (**Entitlement Offer** or **Offer**).

The accelerated institutional component of the Entitlement Offer (**Institutional Entitlement Offer**) raised approximately \$893,235 at the offer price of \$0.04 per new fully paid ordinary share in Bionomics (**New Shares**).

Completion of the Institutional Entitlement Offer represents the first stage of Bionomics' Entitlement Offer, which is expected to raise approximately \$2,173,320 (before costs). The net proceeds of the Entitlement Offer are intended to be used to partially fund a second Phase 2 trial by Bionomics in Post-Traumatic Stress Disorder.

New Shares subscribed for under the Institutional Entitlement Offer are expected to be settled on Monday, 5 October 2020 and to be issued and commence normal trading on the ASX on Tuesday, 6 October 2020. New Shares issued under the Entitlement Offer will rank pari passu with existing Bionomics shares.

Bionomics' Executive Chairman, Dr Errol De Souza said:

*"We are extremely pleased with the support for the Entitlement Offer from our existing institutional shareholders. The success of the Offer is testament to Bionomics shareholders' confidence in the direction of the Company and the opportunities presented by progressing the development programme for BNC210 for the treatment of PTSD."*

Bionomics expects its trading halt to be lifted today and Bionomics shares to recommence trading on an ex-entitlements basis.

### **Retail Entitlement Offer**

The retail component of the Entitlement Offer (**Retail Entitlement Offer**) is expected to open on Thursday, 1 October 2020 and close at 5:00pm (Adelaide time) on Thursday, 15 October 2020.

Eligible retail shareholders will be able to subscribe for 1 New Share for every 12.54 Bionomics shares held as at 6.30pm (Adelaide time) on the record date of Monday, 28 September 2020, at the same offer price of \$0.04 per New Share as the Institutional Entitlement Offer. Eligible retail

shareholders are shareholders who have a registered address in Australia or New Zealand; are not in the United States or acting for the account or benefit of a person in the United States (to the extent such person holds shares for the account or benefit of a person in the United States); were not treated as an eligible institutional shareholder or ineligible institutional shareholder; and do not hold shares for such a person (to the extent they hold shares for such a person).

Further details about the Retail Entitlement Offer will be set out in a booklet (**Retail Offer Booklet**) which Bionomics expects to lodge with the ASX and despatch to eligible retail shareholders on Thursday, 1 October 2020.

It is important to note that the Retail Entitlement Offer is non-renounceable, and there will be no trading of entitlements. Copies of the Retail Offer Booklet will be available on the ASX website.

Under the Retail Entitlement Offer, eligible retail shareholders may apply for additional New Shares in excess of their entitlement (**Retail Oversubscription Facility**) up to a maximum of 100% of their entitlement at the Offer Price. New Shares not applied for by eligible retail shareholders and eligible institutional shareholders may be offered to other eligible retail shareholders through applications via the Retail Oversubscription Facility. There is no guarantee that applicants under the Retail Oversubscription Facility will receive all or any of the additional New Shares for which they apply. The allocation of additional New Shares under the Retail Oversubscription facility will be subject to the terms set out in the Retail Offer Booklet.

### **Additional Information**

Further details about the Offer are set out in the ASX Announcement and Investor Presentation released to the ASX on Thursday, 24 September 2020.

You should seek appropriate professional advice before making any investment decision. If you have any questions about the Retail Entitlement Offer, please contact the Bionomics Offer Information Line on 1300 556 161 (within Australia) or +61 3 9415 4000 (outside Australia) between 8.30 am and 5.00 pm (Adelaide time) during the Retail Entitlement Offer period.

### **AUTHORISED BY THE BOARD**

#### **FOR FURTHER INFORMATION PLEASE CONTACT:**

Mr Jack Moschakis  
Legal Counsel & Company Secretary  
Bionomics Limited  
31 Dalglish St,  
Thebarton, South Australia  
+61 8 8354 6100

#### **About Bionomics Limited**

Bionomics Limited (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 ( $\alpha 7$ ) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with MSD (known as Merck & Co in the US and Canada) and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

#### **Important information**

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction in which such an offer would be illegal. Neither the entitlements nor the New Shares to be offered and sold in the Entitlement Offer have been, or will be, registered under the U.S. Securities Act of 1933 (**U.S. Securities Act**) or the securities laws of any state or other jurisdiction of the United States. Accordingly, the entitlements may not be exercised or taken up by, and the New Shares may not be offered or sold, directly or indirectly, to, persons in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and any other applicable securities law of any state or other jurisdiction of the United States.